Funding for this research was provided by:
Friends of FSH Research
Received: 22 July 2020
Accepted: 23 December 2020
First Online: 9 January 2021
Ethics approval and consent to participate
: The study was approved by the Human Subjects Committee at the University of Washington, with written informed consent obtained.An independent Safety Monitoring Committee consisting of one neurologist, a rheumatologist experienced in use of immunosuppressive medication, and a pharmacist reviewed safety data every 3 months throughout the trial.
: Written informed consent was obtained from the patient for publication of this Case Report. A copy of the written consent is available for review by the Editor of this journal.
: Drs. Wang reports consultancy for Biogen. Drs. Friedman and Tapscott report consultancy for Fulcrum Therapeutics.